Novel Biomarkers – DDK-1
DKK-1
Dikkopf-1 (DKK-1) is a key regulatory protein involved in bone metabolism. It inhibits signals that promote bone formation, making it a significant indicator in various bone and joint disorders. Elevated or decreased levels of DKK-1 may reflect changes in bone remodelling, positioning it as a valuable biomarker across a wide range of diseases—including rheumatoid arthritis, osteoporosis, osteoarthritis, and certain cancers.
Other Applications
DKK-1 levels can be integrated into diagnostic panels to enhance disease detection and stratify risk:
- Combine with markers like AFP, CEA, CA-125, or CA 19-9 for improved cancer diagnostics
- Monitor bone health in at-risk populations
- Track disease activity in autoimmune conditions like RA and AS
Biochip Array Technology
Randox biochip technology enables precise measurement of sPD-1, providing valuable insights into immune regulation and disease progression.
The Evidence MultiSTAT
Meet the Evidence MultiSTAT
The Evidence MultiSTAT is an easy to use, small footprint analyser facilitating on-site simultaneous detection of multiple biomarkers.
Using chemiluminescence as a measurement principle, the Evidence MultiSTAT consistently delivers accurate results.
With minimal sample preparation required, this versatile benchtop analyser can achieve accurate, quantitative results in minutes.
Meet the Cartridge
The Evidence MultiSTAT cartridge contains the reagents required for the chemiluminescent reaction to take place incorporated into its wells.
The process from sample entry to results can be completed in 2 simple steps, with minimal risk of human error.
No other components are required.
References
Ahmed, S. F., Fouda, N., & Abbas, A. A. (2013). Serum dickkopf-1 level in postmenopausal females: correlation with bone mineral density and serum biochemical markers. Journal of Osteoporosis, Article ID 460210.
Anastasilakis, A. D., Polyzos, S. A., Avramidis, A., Toulis, K. A., Papatheodorou, A., & Terpos, E. (2010). The effect of teriparatide on serum Dickkopf-1 levels in postmenopausal women with established osteoporosis. Clinical Endocrinology, 72(5), 752–757.
Begenik, H., Kemik, A. S., Emre, H., Dulger, A. C., Demirkiran, D., Ebinc, S., & Kemik, O. (2014). The association between serum Dickkopf-1 levels and esophageal squamous cell carcinoma. Human & Experimental Toxicology, 33(8), 785–788.
Chu, T., Teng, J., Jiang, L., Zhong, H., & Han, B. (2014). Lung cancer-derived Dickkopf-1 is associated with bone metastasis and the mechanism involves the inhibition of osteoblast differentiation. Biochemical and Biophysical Research Communications, 443(3), 962–968.
Chung, Y., Li, Z. C., Sun, X. L., et al. (2021). Elevated serum Dickkopf-1 is a biomarker for bone erosion in patients with psoriatic arthritis. Chinese Medical Journal, 134(21), 2583–2588.
Coulson, J., Bagley, L., Barnouin, Y., et al. (2017). Circulating levels of Dickkopf-1, osteoprotegerin and sclerostin are higher in old compared with young men and women and positively associated with whole-body bone mineral density in older adults. Osteoporosis International, 28(9), 2683–2689.
Czepiel, M., Stec, M., Korkosz, M., et al. (2021). Down-regulation of Dkk-1 in platelets of patients with axial spondyloarthritis. Arthritis & Rheumatology, 73(10), 1831–1834.
Daigo, Y. (2007). Dikkopf-1 as a novel serologic and prognostic biomarker for lung and esophageal carcinomas. Cancer Research, 67(6), 2517–2525.
D’Amelio, P., Roato, I., Oderda, M., et al. (2014). DKK-1 in prostate cancer diagnosis and follow up. BMC Clinical Pathology, 14(1), 11.
Daoussis, D., Liossis, S. N., Solomou, E. E., et al. (2010). Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis. Arthritis and Rheumatism, 62(1), 150–158.
Diarra, D., Stolina, M., Polzer, K., et al. (2007). Dickkopf-1 is a master regulator of joint remodeling. Nature Medicine, 13(2), 156–163.
Dong, L. L., Qu, L. Y., Chu, L. Y., et al. (2014). Serum level of DKK-1 and its prognostic potential in non-small cell lung cancer. Diagnostic Pathology, 9, Article 52.
Fassio, A., Idolazzi, L., Viapiana, O., et al. (2017). In psoriatic arthritis Dkk-1 and PTH are lower than in rheumatoid arthritis and healthy controls. Clinical Rheumatology, 36(10), 2377–2381.
Han, S. X., Zhou, X., Sui, X., et al. (2015). Serum Dickkopf-1 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer. Oncotarget, 6(21), 19907–19917.
Honsawek, S., Tanavalee, A., Yuktanandana, P., et al. (2010). Dickkopf-1 (Dkk-1) in plasma and synovial fluid is inversely correlated with radiographic severity of knee osteoarthritis patients. BMC Musculoskeletal Disorders, 11, 257.
Hu, Z., Xu, M., Li, Q., et al. (2012). Adalimumab significantly reduces inflammation and serum DKK-1 level but increases fatty deposition in lumbar spine in active ankylosing spondylitis. International Journal of Rheumatic Diseases, 15(4), 358–365.
Ibrahim, N. H., Abdel-Monem, S. M., Elbarashy, A. W. S., et al. (2020). Study of serum and synovial fluid Dickkopf-1 levels in patients with primary osteoarthritis of the knee joint. Egyptian Rheumatology and Rehabilitation, 47(1), 1–6.
Idriss, N. K., Gamal, R. M., Gaber, M. A., et al. (2020). Joint remodeling outcome of serum levels of Dickkopf-1 (DKK1), COMP, and CTXII in rheumatoid arthritis. Central-European Journal of Immunology, 45(1), 73–79.
Jiang, X. T., Ma, Y. Y., Guo, K., et al. (2014). Assessing the diagnostic value of serum Dickkopf-1 levels in cancer detection: a meta-analysis. Asian Pacific Journal of Cancer Prevention, 15(20), 9077–9083.
Jo, S., Nam, B., Lee, Y. L., et al. (2021). The TNF-NF-κB-DKK1 axis promoted bone formation in the enthesis of ankylosing spondylitis. Journal of Rheumatic Diseases, 28(4), 216–224.